doxapram

Doxapram (Dopram) is a respiratory stimulant that inhibits TASK-1, TASK-3, and TASK-1/TASK-3 heterodimer channels and is used to study ventilatory failure caused by apnea of ​​prematurity and exacerbation of chronic obstructive pulmonary disease.

Doxapram hydrochloride hydrate (Doxapram HCl) effectively inhibits the function of TASK-1, TASK-3, and TASK-1/TASK-3 heterodimeric channels, displaying EC50 values of 410 nM, 37 μM, and 9 μM, respectively.

Doxapram intermediate-1 (Compound II) is a pyrrolidone derivative that significantly stimulates the central nervous system (CXS) and respiratory system in dogs, usually accompanied by varying degrees of blood pressure activity.

Doxapram (hydrochloride) is a respiratory stimulant. It inhibits the function of TASK tandem pore (K2P) potassium channels, with EC50 values of 410 nM for TASK-1 and 37 nM for TASK-3. The compound displays an EC50 of 9 μM in inhibiting TASK-1/TASK-3 heterodimer channel function. Doxapram (hydrochloride) can be used in research on apnea in premature infants.

(+)-Ketodoxapram ((R)-AHR-5955) is an orally active respiratory stimulant. It is applicable in studies related to respiratory system disorders.